Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
edivoxetine
- Development stage
- Phase 3
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Edivoxetine is a highly selective norepinephrine reuptake inhibitor (NRI) developed by Eli Lilly. It was investigated as a treatment for major depressive disorder (MDD), attention-deficit hyperactivity disorder (ADHD), and anxiety disorders. Edivoxetine acts by selectively inhibiting the reuptake of norepinephrine in the central nervous system, thereby increasing its synaptic concentration. The drug reached phase III clinical trials for MDD but failed to demonstrate sufficient efficacy compared to standard treatments and was discontinued for this indication in 2013. Development continues for ADHD, where it is being studied as both adjunctive and monotherapy. Edivoxetine is administered orally and has a pharmacokinetic profile characterized by rapid absorption (Tmax ~2 hours) and a half-life of approximately 4–6 hours[1][2][3][5][7].
- Other names
- edivoxetine hydrochloride
02
Targets
NET (Norepinephrine Transporter)
Beyond the preview
Go deeper on edivoxetine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on edivoxetine.